alirocumab sold brand name praluent medication used secondline treatment high cholesterol adults whose cholesterol controlled diet statin treatment human monoclonal antibody belongs novel class anticholesterol drugs known inhibitors first agent receive fda approval fda approval contingent completion clinical trials better determine efficacy common side effects include nasopharyngitis cold injection site reactions approved medical use united european union alirocumab used secondline treatment lower ldl cholesterol adults severe form hereditary high cholesterol people atherosclerosis require additional lowering ldl cholesterol diet statin treatment administered subcutaneous july known whether alirocumab prevents early death cardiovascular disease prevents heart clinical trial determine outcomes ongoing results expected november new england journal medicine published positive results clinical trial alirocumab according study alirocumab significantly reduced major adverse cardiovascular events associated lower risk death cause hazard ratio hr confidence interval ci us food drug administration fda added indication alirocumab treat adults homozygous familial hypercholesterolemia hofh genetic condition causes severely high intended used alone instead added treatments side effects occurred people treated alirocumab clinical trials occurred frequently placebo included nose throat irritation injection site reactions bruising flulike symptoms urinary tract infection diarrhea bronchitis cough muscle pain soreness available data use alirocumab pregnant women assess risks fetus data use alirocumab works inhibiting binds lowdensity lipoprotein receptor ldlr takes cholesterol circulation binding leads receptor degraded less ldl cholesterol removed circulation inhibiting prevents receptor degraded promotes removal ldl cholesterol subcutaneous administration alirocumab maximal suppression free occurs within hours apparent halflife days inhibition dosedependent antibody distributed circulation eliminated low concentrations binding target higher concentrations proteolytic alirocumab human monoclonal antibody made two disulfidelinked human heavy chains disulfidelinked human light chain approximate molecular weight produced using chinese hamster ovary cells transfected recombinant dna grown importance biological target drug discovery emerged series discoveries led identification protein gene role causing cases familial hypercholesterolaemia mutations present role causing low levels ldl cholesterol mutations discovery validation target set race among pharmaceutical biotech alirocumab discovered regeneron pharmaceuticals using velocimmune many genes coding antibodies replaced human investor presentation regeneron claimed system took months first immunized mice filed slide alirocumab codeveloped sanofi deal made received international nonproprietary name known phase trial results reported new england journal phase trial statin intolerant patients called odyssey ran results presented european society cardiology study alirocumab people taking statins high risk cardiovascular events high ldl cholesterol levels published april study showed significant reduction ldl cholesterol levels patients taking alirocumab oral statins compared placebo patients solely taking oral studies ongoing assess effects alirocumab normocholesterolemic july regeneron sanofi announced purchased priority review voucher biomarin recent rare disease drug approval million voucher cut four months regulatory review time alirocumab part strategy beat amgen market first approval july fda approved alirocumab secondline treatment lower ldl cholesterol adults hereditary high cholesterol people atherosclerosis require additional lowering ldl cholesterol diet statin treatment first approval fda approval contingent completion clinical trials better determine efficacy regeneron amgen filed patent protection monoclonal antibodies companies ended patent litigation us march district court found alirocumab infringed amgens patents amgen requested injunction barring regeneron sanofi marketing alirocumab granted january judge gave regeneron sanofi days appeal injunction went october us court appeals reversed ban ordered new trial finding jury given improper instructions evidence withheld regeneron sanofi allowed continue marketing alirocumab appeals us food drug administration fda granted approval praluent regeneron pharmaceuticals inhibitors approached regulatory approval market analysts estimated overall market drugs could per year alirocumab amgens competing drugs sales per year competitors dividing remaining based estimates annual price alirocumab per time pharmacy benefit managers express scripts cvs caremark recognizing new drugs could help patients otherwise left uncontrolled cholesterol levels recognizing injectable biopharmaceuticals always expensive pills especially expensive generic pills expressed concerns burden new costs health care drug approved july announced price higher analysts predicted pharmacy benefit managers continued expressing concerns insurance companies doctors especially concerned price light fact fda approval based lowering cholesterol alone better health outcomes fewer heart attacks longer treatment people high cholesterol controlled diet statins apheresis similar dialysis person visits clinic month blood mechanically filtered case remove ldl cholesterol treatment costs per month per year price alirocumab determined based part making apheresis longer alirocumab international nonproprietary httpsenwikipediaorgwikialirocumab